Clinical Trial Update: Dysbiosis & Long COVID

View source ↗

Summary

A University of Chicago-sponsored clinical trial examining the role of gut dysbiosis in COVID-19 and long COVID is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Snippet

Sponsor: University of Chicago | Conditions: COVID-19 | Status: RECRUITING